A Growing Need for RWE in China
The production of RWE has been proliferating in China over several years, increasing the need for support
regarding healthcare and policy decisions unique to China.
We offer complete life-cycle services for
RWE-based strategies, including clinical development, regulatory submissions, market access to medical
communication leveraging high-quality real-world data, and innovative technologies. We partner with life
science companies, and we make innovative therapies accessible to patients and generate better
healthcare outcomes in China.
Our Offerings
Degree of evidence demand
Clinical decision Payer decision Regulatory decisioncurrent status of treatment
clinical trial
treatment & disease burden
Cost effectiveness
resources
Prescription habit
effectiveness tracking
effectiveness evaluation
effectiveness
of subdivided group
indications’
effectiveness
of clinical usage
& effectiveness
of generic drugs
Launch
Conditional Pricing
Review
New Competition
New Formulation/
Indication
Competitor Goes Generic
What we do
Retrospective Study
AI-driven evidence solution
Evaluation of prognostic factors
Treatment pattern study
Comparative effectiveness
Safety study
Compliance analysis
Efficacy confirmation of subdivided groups
Disease burden and healthcare resources utilization
Patient-centered Research
Optimized study design & flexible execution
Patient’s preference & willingness to payPatient’s preference on treatment plans
Patient’s expected outcomes
Patient’s WTP
Patient-Reported Outcome (PRO)Quality of Life Scale
Prospective /Registry Study
Intelligent management of
automatic multi-source data
collection technology
Disease registry
Product registry
Post approval safety surveillance (PASS)
Drug intensive monitoring (DIM)
Post authorization commitment (PAC)
津公网安备 12011502000526号